The company markets genetic tests for skin cancer including DecisionDx-Melanoma for identifying high-risk stage I and II cutaneous melanoma patients.
The firm, which markets a clinical immunosequencing assay for leukemia and multiple myeloma, had originally expected to sell its shares at $15 to $17 apiece.
The company is offering around 7.9 million shares of common stock at a price of $17 per share and is granting the underwriters an option to buy an additional 1.2 million shares.
Adaptive currently offers a clinical immunosequencing assay for monitoring minimal residual disease in multiple myeloma and acute lymphoblastic leukemia.
The company expects to offer 6.7 million common shares at a maximum offering price of $16 per share.
The firm plans to use proceeds to fund commercial activities related to its ClonoSeq assay, as well as research into drug discovery and its project to map TCR antigens.
The company plans to sell 7.9 million shares of common stock at $16 per share through its initial public offering.
The expected gross proceeds are more than double what the firm proposed as its original goal for the offering when it filed plans to list its shares in September.
The firm hasn't yet specified how many shares it is offering or at what price but noted that its stock would trade under the Nasdaq symbol TWST.
The company said it plans to list its stock on the Nasdaq under the ticker symbol GH.
Google's Project Nightingale has collected health information on millions of Americans, according to the Wall Street Journal.
An opinion piece at The Hill criticizes the proposed plan to collect DNA samples from migrants at the US border.
Nature News writes that women in chemistry are less likely to have their manuscripts accepted for publication.
In PNAS this week: tRNA fragment signature for chronic lymphocytic leukemia, genomic sites sensitive to ultraviolet radiation in melanocytes, and more.